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Abstract  
Background: The cellular immune system is of pivotal importance with regard to the response to 
severe infections. Monocytes / macrophages are considered key immune cells in infections and 
downregulation of the surface expression of monocytic human leukocyte antigen-DR (mHLA-
DR) expression within the major histocompatibility complex class II reflects a state of 
immunosuppression, also referred to as injury-associated immunosuppression. As the role of 
immunosuppression in coronavirus disease 2019 (COVID-19) disease is currently unclear, we 
seek to explore the level of mHLA-DR expression in COVID-19 patients. 
Methods: In a preliminary prospective monocentric observational study, 16 COVID-19 positive 
patients (75% male, median age: 68 [interquartile range 59-75], APACHE-II score in 9 ICU 
patients: 30 [interquartile range 25-32] with acute respiratory failure were included. Standardized 
quantitative assessment of mHLA-DR on CD14+ cells was performed using calibrated flow 
cytometry at baseline (ICU admission), and at days 3 and 5 after ICU admission. Baseline data 
was compared to hospitalized non-critically ill COVID-19 patients. 
Results: While normal mHLA-DR expression was observed in all hospitalized non-critically ill 
patients (n=7), 89% (8/9) critically ill patients with COVID-19- induced acute respiratory failure 
showed signs of downregulation of mHLA-DR at ICU admission. Monocytic HLA-DR 
expression at admission was significantly lower in critically ill patients (median, [quartiles]: 9280 
antibodies/cell [6114, 16567]) as compared to the non-critically ill patients (30900 antibodies/cell 
[26777, 52251]), with a median difference of 21508 antibodies/cell (95% CI: 14118 to 42971), 
P=0.002. Reduced monocytic HLA-DR expression was observed to persist until day 5 after ICU 
admission. 
Conclusions: When compared to non-critically ill hospitalized COVID-19 patients, ICU patients 
with severe COVID-19 disease showed reduced mHLA-DR expression on circulating CD14+ 
monocytes at ICU admission, indicating a dysfunctional immune response. This 
immunosuppressive (monocytic) phenotype remained unchanged over the ensuing days after ICU 
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admission. Strategies aiming for immunomodulation in this population of critically ill patients 
should be guided by an immune-monitoring program in an effort to determine who might benefit 
best from a given immunological intervention. 
Key words: SARS-CoV-2, COVID-19, intensive care unit, ICU, critical illness, 
immunodepression, immunosuppression, sepsis-associated immunosuppression.  
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Glossary of Terms:  
CD (14+): Cluster of differentiation (14+) 
COVID-19:  Coronavirus Disease 2019  
EDTA: Ethylenediaminetetraacetic acid 
FACS:  Fluorescence-activated cell sorting 
FSC:  Forward scatter 
ICU:   Intensive care unit 
PCR:  polymerase chain reaction 
PE:  Phycoerythrin 
SARS -CoV-2: Severe acquired respiratory syndrome coronavirus-2 
SSC:  Side scatter  
Key points:  
Question: Is severe COVID-19 disease associated with an immunosuppressive phenotype of key 
innate immune cells ? 
Findings: We observed considerable reduction of mHLA-DR, a key marker of monocytic 
immune function, in critically ill COVID-19 patients with acute respiratory failure and this effect 
remained unchanged over the first days on the ICU. 
Meaning: Severe COVID-19 disease is associated with reduced HLA-DR expression on 
circulating CD14+ cells, indicating a dysfunctional immune response. Future strategies aiming for 
immunomodulation in this population of ICU patients should be guided by an immune-
monitoring program in an effort to determine who might potentially benefit from a targeted 
immunological intervention.  AC
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INTRODUCTION 
In higher life forms, the immune system is organized in complex social network architecture-like 
structures 1 and its dysfunction is associated with adverse outcomes in various clinical scenarios. 
Although detection and monitoring of various organ dysfunctions is a key challenge for 
physicians involved in the care for the critically ill, the immune system may currently be regarded 
somewhat overlooked as it is typically not monitored within the clinical routines of most intensive 
care units (ICUs). This may be of particular importance in critically ill patients with severe 
infections (e.g. patients with bacterial septic shock) 2-7.  
Data show that monocytes / macrophages play key roles in critically ill patients with 
severe infections and constitute a first line cellular response that initiates and promotes a targeted, 
i.e. adaptive, immune response 2,3,8. In this regard, flow cytometry-based standardized assessment 
of the surface expression of monocytic human leukocyte antigen-DR (mHLA-DR) was proposed 
by us and others 2,9,10 to serve as a global marker of (monocytic) immune function as it reflects 
key cell-mediated immune functions including major histocompatibility complex (MHC) class II-
mediated antigen-presentation, ex-vivo cytokine release, and phagocytosis) 2,3,6,8,10. Monocytic 
HLA-DR expression can be assessed in a quantitative fashion using a standardized assay 
(coefficient of variation <4% intra-lab and 15% inter-lab) 11, allowing for multi-center data 
comparison 9. Importantly, mounting data from critically ill patients with (bacterial) sepsis/ septic 
shock show that reduced mHLA-DR expression (indicating “injury-associated 
immunosuppression” 3) is associated with adverse clinical outcomes in ICU patients, including 
increased rates of secondary infections, and increased mortality 2,12-15. Further, mHLA-DR 
previously served to guide targeted immunological interventions e.g. using immunostimulatory 
approaches 16-18 or via reduction of inhibitory factors 19. Such biomarker enrichment 20 may allow 
for identification of which patient might benefit best from a given immunomodulatory 
intervention 2,6,7,14. 
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 From an epidemiological perspective, COVID-19 (SARS -CoV-2) patients appear 
(clinically) well characterized 21-24. However, the role of virus- induced immunosuppression 
remains incompletely understood 25. We therefore embarked to investigate the role and course of 
monocytic HLA-DR expression in ICU patients with severe COVID-19 disease, i.e. critically ill 
patients. This is performed as understanding of the immunologic phenotype will be important e.g. 
when immunomodulatory immunotherapies are evaluated. 
METHODS 
In a preliminary prospective monocentric observational study, patients with confirmed COVID-
19 disease were included from March until April 2020 and followed up until ICU-/ hospital 
discharge and/or death. Patients were initially assessed for eligibility in the emergency rooms 
(non-critically ill patients), or at the ICU (in cases of direct ICU admission). The study was 
performed in an 900+ bed tertiary care academic medical center (Inselspital, Bern University 
Hospital, Switzerland). In this center, the Department of Intensive Care Medicine is the sole 
provider of intensive care medicine for adults.  
Adult (aged ≥ 18 years) patients with confirmed SARS-CoV-2 infection (detected by PCR in 
nasopharyngeal swabs) were consecutively included in the study after provision of informed 
consent (in case of lack of capacity and/or inability to provide consent, consent followed the local 
procedures for research projects in emergency situations). Screening of patients was performed in 
daily clinical practice by the research team. The following exclusion criteria applied: no 
confirmed SARS-CoV2 infection or confirmed SARS-CoV2 infection > 3 days before inclusion, 
age <18 years, lack of consent. No financial compensation applied for participants. Hospitalized 
patients and ICU patients were followed up until ICU or hospital discharge, or death (while in 
hospital). Laboratory data was recorded with missing data indicated. Lab samples were drawn at 
the scheduled visits within ±36 hours. Data available until April 30, 2020 (censor date) was 
included. The trial was performed in accordance with the “Declaration of Helsinki” and approved 
by the Kantonale Ethikkommission KEK, Bern, Switzerland, Nr. 2020-00877.  
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Flowcytometric Assessment of mHLA-DR expression 
Flow-cytometric assessment of mHLA-DR expression (primary outcome) was performed from 
EDTA samples within 4 hours, as previously reported 11 (discussed in 3,9). In brief, a mixture that 
contains beads with pre-defined amounts of conjugated antibodies (Phycoerythrin molecules, PE) 
is measured using the same FACS instrument settings (as the cells of interest) using a mixture of 
anti-human HLA-DR-PE, anti-human CD14-PerCP-Cy5.5, and an inhibitor of HLA-DR turnover 
(QuantibriteTM HLA-DR/ Monocyte reagent, Becton Dickinson, Franklin Lakes, USA) 11. The 
known ratio of PE to anti-HLA-DR antibody is applied to convert PE molecules/ cell into 
antibodies/ cell 3,9,11 with the anti-CD14 antibody detecting all monocytes (CD14 bright and weak 
positive) 11. The gating strategy is given in Figure 1. 
Statistics 
Data were analyzed with Stata 16.1 (StataCorp, College Station, TX, USA). The distribution of 
continuous data was assessed with histograms, Q-Q plots and Shapiro-Wilk tests. All continuous 
data departed from the normal distribution and are presented as median [quartiles]. Baseline 
demographic data, laboratory data and follow-up data were compared between the groups with 
Mann-Whitney U tests (continuous data) or with Fisher’s exact test (categorical data; all had 
expected counts <5 in ≥ 25% of cells).  
The primary outcome, mHLA-DR expression at admission, was compared between the groups 
(patients admitted to the general ward versus patients admitted to the ICU) using a Mann-Whitney 
U test 26. The median difference between the groups and its 95% confidence interval were 
estimated with the Hodges-Lehmann estimator. Being aware that our small dataset does not lend 
itself to multiple regression modeling, we yet performed explorative analyses to gauge potential 
confounding due to differences in baseline characteristics between groups 27,28. We used quantile 
(median) regression, as well as linear regression with bootstrapped standard errors (10,000 
replications), to adjust for age, sex and BMI.  
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One patient was first admitted to the normal ward and subsequently to the ICU after clinical 
deterioration. According to the primary admission, this patient is considered a non-critically ill 
patient for the comparison of mHLA-DR expression at admission. We also performed a 
sensitivity analysis in which the patient was analyzed as being an ICU patient.  
In ICU patients, follow up data for mHLA-DR expression were obtained at days 3 and 5 of their 
ICU admission. Differences over time were tested with the Skillings-Mack test. This test is an 
extension of the Friedman test (nonparametric equivalent to one-way repeated measures analysis 
of variance) that allows for missing data. Two-sided p<0.05 was considered statistically 
significant. For this preliminary investigation, a formal a priori power analysis/sample size 
calculation was not performed, and the sample size is based on the available number of patients. 
RESULTS 
Sixteen patients (12 male, median age 68 years) were included in this preliminary observational 
study, of which 9 were primarily admitted to the ICU for mechanical ventilation, and 7 with 
primary hospitalization at the general ward. Table 1 shows demographic data, comorbidities, 
laboratory data, as well as follow-up data for both patient groups. While the table suggests 
clinically relevant differences in terms of infection parameters and length of hospital stay in our 
sample of patients, there was insufficient evidence to claim a significant difference in the 
population of patients from which the data were sampled (all P-values >0.05).  
Monocyte HLA-DR expression at admission was significantly lower in the ICU-group (9280 
antibodies / cell [6114, 16567]) as compared to the non-ICU group (30900 antibodies /cell 
[26777, 52251]), with a median difference of 21508 antibodies /cell (95% CI: 14118 to 42971), 
P=0.002 (Figure 2). Similarly, the adjusted quantile regression and linear regression provided 
evidence for a significant between-group difference (P=0.001 and P<0.001, respectively).  
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The sensitivity analysis, in which one patient of the non-ICU group was counted towards the ICU 
group as described above, provides consistent results in the unadjusted analysis (median 
difference 19419 antibodies/cell, 95% CI: 8487 to 43578, P=0.016) as well as in the adjusted 
analyses (P=0.001 and P=0.007, respectively). 
In ICU patients, median mHLA-DR expression was 9280 antibodies / cell [6114, 16567] at 
admission (N=9), 9672 antibodies / cell [8253, 10511] at 3 days (N=9), and 7334 antibodies / cell 
[5241, 11022] at 5 days (N=6), without evidence for a change over time (P=0.33, Figure 3). 
Including the admission-measurement of the patient who was initially admitted to the normal 
ward and who was later admitted to the ICU, median HLA-DR expression was 9944 antibodies / 
cell [6114, 16782] at admission (N=10), still without evidence for a change over time (P=0.19).  
DISCUSSION 
We demonstrate immunosuppression of key innate immune cells in critically ill patients with 
(severe) COVID-19. Monocytic HLA-DR expression was reduced on circulating CD14+ cells, 
and this was not observed in hospitalized COVID-19 patients without critical illness. Importantly, 
this initial effect persisted over the ensuing days of ICU treatment (until day 5). Of note, all study 
individuals were treatment-naïve regarding immunomodulatory agents and/ or high-dose 
corticosteroids. In the light of the current multiple immunomodulatory interventional approaches 
tested in COVID-19 25, it seems essential that patients are adequately immunologically 
characterized using immunological read-outs in an effort to determine which patient might benefit 
best from a given immunomodulatory intervention. Thus, injury-associated immunosuppression 
should be taken into account when novel immunomodulatory interventions are designed and 
tested in critically ill patients with COVID-19. 
Our current data show that immunosuppression presented as early as at ICU admission and the 
observed downregulation of mHLA-DR did not change significantly over the ensuing days of 
ICU treatment (i.e. at least until day 5 after ICU admission). This seems of particular interest, as 
when compared to ICU patients with (bacterial) septic shock, decreased mHLA-DR expression is 
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mostly observed after a few days following ICU admission and may be most prominent after 
about 72 hours (reviewed in 3). Although the exact onset of disease can mostly not be elucidated 
in critically ill patients, it is known that the median incubation period of SARS-CoV-2 is about 4-
5 days 21-24 and about 97.5% of patients diagnosed with COVID-19 develop symptoms within the 
first 11.5 days 22. In the light of the specific disease investigated, it thus seems tempting to 
speculate that downregulation of mHLA-DR would typically occur prior to development of acute 
respiratory failure, i.e. before ICU admission in severe COVID-19 disease and mHLA-DR 
assessment could theoretically provide early prognostic information. Moreover, and importantly, 
the immunosuppression reflected in decreased mHLA-DR might theoretically be a relevant 
contributor to progression of increased viral replication and/or the severity of the viral disease. 
Previous data from ICU patients with bacterial septic shock show that secondary infection rates 
are increased in patients with persistent downregulation of mHLA-DR, i.e. injury-associated 
immunosuppression (reviewed in 3,6). Thus, as secondary infections contribute to increased 
morbidity and mortality in ICU patients with COVID-19 disease, the potential association of 
mHLA-DR downregulation with secondary infection rates should be investigated in subsequent 
investigations. Importantly, however, in the current analysis, we are unable to conclude back on 
causality and/or effects on secondary infection rates due to the limited sample size and the 
preliminary, observational nature of the investigation. 
Further, our observations might challenge the concept of a general macrophage activation 
syndrome as being a primary driver of severe COVID-19 disease. In the current observational 
study, we observed macrophage “deactivation” as indicated by reduced expression of MHC class 
II (HLA-DR) on CD14+ cells, rather than macrophage activation. However, due to the limited 
sample size and monocentric character of the investigation, this awaits confirmation in 
subsequent larger analyses.   
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A number of additional limitations of this analysis deserve discussion. First, consecutive patients 
were included in a single-center observational study and all respective limitations (driven by 
study design) apply. Second, the sample size was limited and results await confirmation in 
subsequent larger cohorts. However, the limited sample size was partly due to the fact that 
informed consent cannot easily be achieved during a pandemic in the cohort investigated. 
Nevertheless, observed effects on mHLA-DR expression were consistent and strong, likely 
pointing to an important disease-immanent process.  
Third, final outcome data was not available for 3 patients with long-term ICU stay. However, 
although a final data set might have been preferable, it may underline the relevance of 
immunosuppression in this context. Fourth, follow-up data at days 3 and 5 of non-critically ill 
hospitalized patients would have been interesting, but were unavailable (also for the fact that 
patients improved rapidly) to obtain such samples as patients were discharged from our 
institution. Fifth, longer follow-up, i.e. until all ICU patients have recovered, would have been 
preferable, however, this was initially deemed not possible and out of the scope of the current 
investigation. Nevertheless, we are therefore unable to conclude on the potential recovery slope of 
mHLA-DR in survivors of critical illness and suppose that this should be investigated in 
subsequent larger studies. Sixth, one might speculate whether monocyte deactivation would be a 
phenomenon of the blood compartment, rather than to reflect monocytic immune function in 
“solid immune organs”. However, it was previously shown in patients with bacterial sepsis, that 
HLA-DR downregulation would not only be observed in the blood compartment, but would rather 
be paralleled in respective “solid immune organs” 15. 
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In conclusion, in a prospective monocentric study with a limited sample size, we observed that 
severe COVID-19 disease is associated with considerable and sustained immunosuppression of 
key innate immune cells (monocytes / macrophages), indicating a dysfunctional immune response 
in a majority of critically ill patients. This phenotype persisted over the initial days of ICU 
treatment and may underline the urgent need for an adequate immunological characterization 
(using appropriate immunological read-outs) when targeted immunomodulatory interventions are 
tested in respective critically ill patients.  
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Figure Legends 
Figure 1 Flow cytometric analysis of HLA-DR expression in COVID-19 patients  Gating 
strategy: key steps in measurement of monocytic HLA-DR expression using standardized 
assessment. Beads are gated on their SSC and FSC characteristics (not shown), and PE 
fluorescence is plotted (A). Patient’s monocytes are gated by CD14-binding and SSC properties 
(B), mHLA-DR expression is plotted against CD14 to calculate the median HLA-DR expression 
(C). 
Figure 2  Monocytic HLA-DR expression in hospitalized patients with COVID-19 
MHLA-DR expression (given in antibodies / cell, Ab / cell) at normal ward (n=7) versus primary 
ICU admission (n=9), p=0.002 in Mann-Whitney U test. 
Figure 3  Expression of monocytic HLA-DR over time in patients hospitalized on the 
ICU Available data (presented in antibodies / cell, Ab/ cell) are given at ICU admission, and days 
3 and 5. Discharge from ICU (until day 5) and transfer from the normal ward to ICU is included.  
Table Legends  
Table 1 Patient demographics, disease severity, and clinical outcomes Demographical data, 
baseline comorbidities, laboratory data, and clinical follow-up is given for patients with primary 
admission to ICU vs. normal ward (until censor date). G= Giga, L= Liters, APACHE-II= Acute 
Physiology and Chronic Health Evaluation- II score, SAPS-2= Simplified Acute Physiology 
Score-2, SOFA= Sepsis-related organ failure assessment score, COPD= chronic obstructive 
pulmonary disease, HIV= human immunodeficiency virus, AIDS= acquired immunodeficiency 
syndrome. Numbers (No.) with percentages are given, as indicated.  Continuous data are reported 
as median [quartiles]. Between group p-values from Mann-Whitney U tests and Fisher’s exact 
tests are given for ICU vs. non-ICU (normal ward) populations. * Mortality data available from 7 
ICU patients. Between group p-values are given for ICU vs. non-ICU (normal ward) populations. 
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Table 1: Baseline demographics, disease severity, and clinical outcome.  
 
ICU patients 
with  
COVID-19  
(n=9) 
Hospitalized 
COVID-19 
patients 
(n=7) 
Total cohort 
(n=16) 
between 
group  
p-value 
Demographics - Age (years) 66 [62, 77] 71 [55, 73] 68 [59, 75] 0.98 
- Gender (male, %) 6 (67%) 6 (86%) 12 (75%) 0.59 
- Body Mass Index 26.9 [26.0, 27.8] 26.3 [24.4, 27.9] 26.6 [25.1, 27.9] 0.59 
- APACHE-II score (first 24 hours) 30 [25, 32] - - - 
- SAPS II score (first 24 hours) 69 [66, 78] - - - 
- SOFA score (baseline) 13 [13, 15] - - - 
Comorbidity 
data 
- Charleson Comorbidity Index    
    (total score) 
3 [2, 6] - - - 
- Myocardial infarction (No./%) 1 (11%) - - - 
- Chronic heart failure (No./%) 0 (0%) - - - 
- Peripheral vascular disease (No./%) 1 (11%) - - - 
- Cerebrovascular accident (No./%) 1 (11%) - - - 
- Dementia (No./%) 0 (0%) - - - 
- COPD (No./%) 3 (33%) - - - 
- Connective tissue disease (No./%) 0 (0%) - - - 
- Peptic ulcer disease (No./%) 0 (0%) - - - 
- Liver disease (0-3) (No./%) 0 (0%) - - - 
- Diabetes (0-2) (No./%) 2 (22%) - - - 
- Hemiplegia (No./%) 0 (0%) - - - 
- Moderate to severe CKD (No./%) 2 (22%) - - - 
- Solid tumor (0-6) (No./%) 0 (0%) - - - 
- Leukemia (No./%) 0 (0%) - - - 
- Lymphoma (No./%) 0 (0%) - - - 
- HIV/ AIDS (No./%) 0 (0%) - - - 
Laboratory 
data 
- C-reactive protein (mg/L) 149 [96, 243] 43 [7, 126] 120 [31, 197] 0.07 
- Procalcitonin levels (ng/ml) 0.4 [0.2, 1.2] 0.2 [0.1, 0.3] 0.3 [0.2, 0.5] 0.09 
- Total leukocyte count (G/L) 7.0 [4.7, 7.7] 6.9 [5.2, 8.5] 6.9 [5.0, 8.1] 0.92 
- Total lymphocyte count (G/L) 0.8 [0.6, 0.9] 1.2 [1.0, 1.9] 1.0 [0.8, 1.7] 0.06 
- Platelet count (G/L) 192 [143, 225] 185 [174, 267] 189 [166; 234] 0.47 
- Serum potassium (mmol/L) 3.9 [3.6, 4.2] 3.7 [3.6, 4.2] 3.8 [3.6, 4.2] 0.42 
- Serum creatinine (µmol/L) 102 [76, 134] 79 [62, 97] 95 [67, 105] 0.14 
 - D-Dimers (µg/L) 1340 [982, 1973] 490 [428, 2062] 1233[574, 2062] 0.28 
Follow-up  
 
- Days on ICU 11.8 [8.3, 23.0] - - - 
- Days in hospital 17 [9, 24] 6 [4, 14] 10.5 [4.5, 20.0] 0.07 
- Total days on antibiotics 6 [4, 8] 4 [1, 12] 4.5 [1.5, 9.0] 0.49 
- Total days on mechanical ventilation  9 [5, 23] - - - 
- Renal replacement at any time    
     (No./%) 
3 (33%) - - - 
- On vasopressors at any time  
     (No./%) 
8 (89%) - - - 
- Total norepinephrine dose  
    (cumulative dose/ ICU days; mg) 
3.4 [1.3, 6.8] - - - 
- ICU Mortality (No./%) 2/7 (29%)* - - - 
- Hospital mortality (No./%) 2/7 (29%)* 0 (0%) 2/14 (14%) 0.46 
Demographical data, baseline comorbidities, laboratory data, and clinical follow-up is given for patients with primary 
admission to ICU vs. normal ward (until censor date). G= Giga, L= Liters, APACHE-II= Acute Physiology and Chronic 
Health Evaluation- II score, SAPS-2= Simplified Acute Physiology Score-2, SOFA= Sepsis-related organ failure 
assessment score, COPD= chronic obstructive pulmonary disease, HIV= human immunodeficiency virus, AIDS= 
acquired immunodeficiency syndrome. Numbers (No.) with percentages are given, as indicated.  Continuous data 
are reported as median [quartiles]. Between group p-values from Mann-Whitney U tests and Fisher’s exact tests are 
given for ICU vs. non-ICU (normal ward) populations. * Mortality data available from 7 ICU patients. Between group 
p-values are given for ICU vs. non-ICU (normal ward) populations. 
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